一项针对IVF中高龄产妇患者的荟萃分析与系统综述
该系统综述检索Embase、Medline和Cochrane Library(1985年1月至2024年9月),纳入151项研究,评估IVF中不同干预措施对高龄产妇(AMA)患者临床结局的疗效。多数证据显示特定刺激方案、FSH药物、ICSI和PGT-A无常规实施优势,辅助孵化(AH)荟萃分析提示活产率降低。
要点
- AMA在所有研究中未统一定义,但共同点为年龄大于35岁。
- 辅助孵化(AH)的荟萃分析提示活产率降低。
- PGT-A的荟萃分析提示活产率与未检测相似。
核心结论
- 本综述未发现常规实施特定刺激方案、促性腺激素、ICSI和PGT-A的优势,辅助孵化(AH)可能存在潜在有害效应。
- 需要未来高质量随机对照试验来确认本综述的多数结论。
研究设计与样本
- 系统综述与荟萃分析,检索Embase、Medline和Cochrane Library,纳入1985年1月至2024年9月发表的英文同行评议原创文章。
- 共纳入151项研究,主要设计为评估IVF中不同干预措施对AMA患者临床结局的疗效。
- 对存在足够随机对照试验的干预措施进行荟萃分析。
主要发现
- AMA在所有研究中未统一定义,但共同点为年龄大于35岁。
- 对多数证据而言,AMA患者中任何刺激方案似乎均无明确优势。
- 任何特定FSH药物似乎均无优势;在刺激中向FSH添加LH的荟萃分析显示临床妊娠率和活产率相似。
- 未发现良好证据支持在AMA患者中常规实施ICSI;辅助孵化(AH)的荟萃分析提示活产率降低。
- 低质量证据显示移植多个胚胎可增加活产率,同时增加多胎妊娠分娩;PGT-A的荟萃分析提示活产率与未检测相似。
临床怎么用
- 本综述未发现常规实施特定刺激方案、促性腺激素、ICSI和PGT-A的优势,辅助孵化(AH)可能存在潜在有害效应。
- 需要未来高质量随机对照试验来确认本综述的多数结论。
局限性
- AMA在所有研究中未统一定义。
- 需要未来高质量随机对照试验来确认本综述的多数结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There has been an increase in the average age of patients seeking fertility treatments over the past decades, with a significantly higher rate of advanced maternal age (AMA) patients undergoing IVF. It is unclear if different treatment strategies in IVF improve outcomes in AMA patients. OBJECTIVE AND RATIONALE: The aim of this systematic review was to assess the efficacy of different interventions employed in IVF in patients of AMA. SEARCH METHODS: A comprehensive search in Embase, Medline, and the Cochrane Library was performed. The search strategy included keywords related to IVF and AMA. We included all original peer-reviewed articles published in English, from January 1985 to September 2024, primarily designed to assess the efficacy of different interventions in IVF on clinical outcomes in AMA patients. Meta-analyses were performed for interventions for which sufficient randomized controlled trials existed. OUTCOMES: A total of 151 studies were included in the review. AMA was not consistently defined in all studies reviewed, although common to all studies was an age above 35 years. For the majority of evidence, there appeared to be no clear advantage to any stimulation protocol in AMA patients. There also appeared to be no advantage to any specific FSH medication, while a meta-analysis performed for the addition of LH to follicular stimulating hormone in stimulation demonstrated similar clinical pregnancy and live birth rates. No good evidence was found to support the routine implementation of ICSI in AMA patients, while a meta-analysis performed for assisted hatching (AH) pointed to decreased live birth rates with its implementation. Low-quality evidence demonstrated an increase in live birth rates with multiple embryos transferred with an increase in multiple pregnancies delivered. Finally, a meta-analysis performed for preimplantation genetic testing for aneuploidy (PGT-A) pointed to similar live birth rates as for no testing. WIDER IMPLICATIONS: This review failed to find an advantage to the routine implementation of treatment strategies such as specific stimulation protocols and gonadotropins, ICSI, and PGT-A, and a potential harmful effect for AH. Future high-quality randomized controlled trials are needed to affirm the majority of this review's conclusions. REGISTRATION NUMBER: PROSPERO ID: CRD42022335889.
引用
- Ganer Herman H, Feferkorn I, Dahan MH, et al. A meta-analysis and systematic review of advanced maternal age patients in IVF. Hum Reprod Update. 2025. PMID: 40803331. doi:10.1093/humupd/dmaf020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。